<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Items</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m. (15 minutes + 5 minute discussion)</td>
<td><strong>Opening remarks and introductions</strong>&lt;br&gt;Defining rapid reviews and how they differ from other knowledge synthesis approaches</td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>1:50 p.m. (30 minutes + 5 minutes for Q&amp;A)</td>
<td><strong>Tailoring rapid review methods according to the decision-maker needs</strong></td>
<td>Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko</td>
</tr>
<tr>
<td>2:25 p.m. (30 minutes)</td>
<td><strong>Group Activity 1: Scenario</strong>&lt;br&gt;Learners (groups of 5-7) will be given a scenario of a COVID-19-related topic from a decision maker. They will be asked to tailor the methods to answer the research question.</td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>2:55 p.m. (10 minutes)</td>
<td><strong>Health Break</strong></td>
<td></td>
</tr>
<tr>
<td>3:05 p.m. (15 minutes)</td>
<td><strong>Discerning how to assess the quality of rapid reviews</strong></td>
<td>Dr. Nancy Santesso</td>
</tr>
<tr>
<td>3:20 p.m. (30 minutes + 5 minutes for Q&amp;A)</td>
<td><strong>Effectively engaging patient and public partners in rapid reviews</strong></td>
<td>Ms. Maureen Smith Dr. François-Pierre Gauvin</td>
</tr>
<tr>
<td>3:55 p.m. (30 minutes)</td>
<td><strong>Group Activity 2: Scenario</strong>&lt;br&gt;Learners (groups of 5-7) will be given a rapid review scenario for which they will come up with a strategy on how to meaningfully involve patient partners.</td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>4:25 p.m. (5 minutes)</td>
<td><strong>Closing Remarks</strong></td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td><strong>Adjourn</strong></td>
<td></td>
</tr>
</tbody>
</table>
Acknowledgement of Traditional Land

- We wish to acknowledge the traditional land on which the Central Coordinating Office of the SPOR Evidence Alliance operates, now known as “Toronto”.

- For thousands of years it has been the traditional land of the Huron-Wendat, the Seneca, and the Mississaugas of the Credit.

- Today, this meeting place is still the home to many Indigenous people from across Turtle Island and we are grateful to have the opportunity to work on this land.

- June 21st was National Indigenous People’s Day in Canada and this month is a call to honour, acknowledge, and celebrate the diverse Nations and unique cultures of First Nations, Inuit and Métis peoples who have called this land home since time immemorial.
Acknowledging Remains of Indigenous Children found in Former Residential School Sites in Canada

- During this National Indigenous History Month, we continue to grieve for the Indigenous children who lost their lives at residential schools across Canada.

- Our thoughts are with the families, their nations, and all survivors of residential schools.

- We urge everyone to spend time learning about the history and the effects of residential schools in Canada.

- It is also a time to reflect on our ongoing roles and responsibilities towards Truth and Reconciliation with Indigenous peoples and to take steps towards decolonization and anti-oppression.
Learning Objectives:

1. To define a rapid review and how it differs from other knowledge synthesis approaches.
2. To discuss how to effectively engage patient and public partners in rapid reviews.
3. To describe how to tailor the methods for rapid reviews according to the decision-maker needs.
4. To discern how to assess the quality of a rapid review.

WEDNESDAY
JUNE 30TH
1:30 TO 4:30 P.M. ET
### Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Items</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.</td>
<td><strong>Opening remarks and introductions</strong>&lt;br&gt;Defining rapid reviews and how they differ from other knowledge synthesis approaches</td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>1:50 p.m.</td>
<td><strong>Tailoring rapid review methods according to the decision-maker needs</strong></td>
<td>Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko</td>
</tr>
<tr>
<td>2:25 p.m.</td>
<td><strong>Group Activity 1: Scenario</strong>&lt;br&gt;Learners (groups of 5-7) will be given a scenario of a COVID-19-related topic from a decision maker. They will be asked to tailor the methods to answer the research question.</td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>2:55 p.m.</td>
<td>Health Break</td>
<td></td>
</tr>
<tr>
<td>3:05 p.m.</td>
<td><strong>Discerning how to assess the quality of rapid reviews</strong></td>
<td>Dr. Nancy Santesso</td>
</tr>
<tr>
<td>3:20 p.m.</td>
<td><strong>Effectively engaging patient and public partners in rapid reviews</strong></td>
<td>Ms. Maureen Smith&lt;br&gt;Dr. François-Pierre Gauvin</td>
</tr>
<tr>
<td>3:55 p.m.</td>
<td><strong>Group Activity 2: Scenario</strong>&lt;br&gt;Learners (groups of 5-7) will be given a rapid review scenario for which they will come up with a strategy on how to meaningfully involve patient partners.</td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>4:25 p.m.</td>
<td><strong>Closing Remarks</strong></td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Defining Rapid Reviews and How They Differ from Other Knowledge Synthesis Approaches

Andrea Tricco PhD, MSc
Director & Scientist, Knowledge Synthesis Team, Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto
Associate Professor, Dalla Lana School of Public Health & Institute of Health Policy, Management, and Evaluation, University of Toronto
Co-Director & Adjunct Associate Professor, Queen’s Collaboration for Health Care Quality Joanna Briggs Institute Centre of Excellence, Queen’s University
Poll Question

- Let’s pause for a quick poll.
- Respond to the following question by placing your answer in the chat box.

How much experience do you have with knowledge synthesis (KS)?

1. I have no experience with KS
2. I have some experience with KS
3. I have lots of experience with KS
What is a Knowledge Synthesis?

- Also called **Evidence Synthesis**

- **Knowledge synthesis** uses specific, rigorous and transparent methods to **bring together information from multiple studies** that have looked at the same topic to make sense of their findings.

- It is an **umbrella term** used to represent a family of synthesis approaches such as systematic reviews, scoping reviews, rapid reviews, living evidence profiles, etc.
We often hear about these 5 common types of knowledge syntheses…

1. Systematic reviews
2. Network meta-analysis
3. Scoping reviews
4. Overview of reviews
5. Rapid reviews
Queries are Matched to a Knowledge Synthesis Method

- **What Review is Right for You tool:**
  - 8 types of knowledge synthesis methods:
    - Overviews, rapid, systematic, network meta-analysis, epidemiological, prognostic, diagnostic, economic

https://whatreviewisrightforyou.knowledgetranslation.net/
Why are Knowledge Syntheses Important?

- Basing decisions on expert opinion can be biased
- Difficult for knowledge users to keep up with the literature
- Basing decisions on findings of an individual study might be misleading
- Knowledge synthesis can be used to statistically combine the results of multiple studies, increasing our confidence in the results (power and precision), and can be used to sort through results arising from conflicting studies.

2. Ioannidis et al. (2005): JAMA
What is a Rapid Review?

- A type of knowledge synthesis that has emerged out of a need to synthesize information quickly to inform urgent decision needs in health care.

- A term used to describe an approach to simplifying or skipping some steps of a traditional knowledge synthesis to produce information in a timely manner.

- It is important to document steps that were streamlined to improve transparency of how the research was conducted.
What type of rapid evidence products are feasible?

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inventories</strong></td>
<td>Inventories only list the evidence that is available on a given topic. There is no attempt to appraise, summarize or synthesize the evidence for further use, nor is there an attempt to present conclusions or recommendations to the knowledge user.</td>
</tr>
<tr>
<td><strong>Rapid response briefs</strong></td>
<td>Rapid response briefs present a summary of the best available evidence in a synthesized and contextualized manner, in direct response to a decision-maker’s question. They are knowledge translation products created through formal methods to synthesize and appraise the evidence. They do not generate new knowledge but use findings that are already available, especially from existing systematic reviews.</td>
</tr>
<tr>
<td><strong>Rapid reviews</strong></td>
<td>Rapid reviews represent a knowledge generation strategy. They synthesize findings and assess the validity of research evidence using “abbreviated” systematic review methods, modifying these methods to generate evidence in a short time.</td>
</tr>
</tbody>
</table>

***Most relevant rapid review approaches are rapid scoping reviews, rapid overview of reviews, rapid (systematic) review***
Rapid Review Steps

- Discuss policy, practice, and clinical implications with caution
- Provide a more streamlined product (e.g., 1-page summaries)
- Limit the number of tables and text used to describe study and patient characteristics
- Limit to basic descriptive summary of studies
- Prioritize type of analysis

Protocol Development

- Develop research question using PICOST
- Determine eligibility criteria using the PICOST research question
- Plan a literature search
- Only register protocol

Abstract Data

- Prioritize assessment of key sources of bias
- Streamline by limiting to a single reviewer and one verifier
- (Skip this step)

Critical Appraisal and assessment

- Summarize study and patient characteristics

Synthesize results

- Limit the number of tables and text used to describe study and patient characteristics
- Prioritize assessment of key sources of bias

Present results

- Discuss policy, practice, and clinical implications with caution

Literature Search

- Limit literature search (e.g., # of databases, by date, grey lit)
- Use a layered search approach

Level 1 and Level 2 screening

- Level 1: Titles and abstracts
- Level 2: Full-text articles

Pilot the form

- Use two reviewers for some of the data points to be abstracted
- Limit to a single reviewer only or single reviewer and one verifier

Status | Patients, n (%) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharged from emergency department</td>
<td>140 (25)</td>
</tr>
<tr>
<td>Discharged after observation period</td>
<td>44 (8)</td>
</tr>
<tr>
<td>Transferred to other health facility</td>
<td>6 (1)</td>
</tr>
<tr>
<td>Died in emergency department</td>
<td>1 (0)</td>
</tr>
<tr>
<td>Hospitalized</td>
<td>78 (20)</td>
</tr>
<tr>
<td>Discharged within the first 3 days</td>
<td>112 (30)</td>
</tr>
<tr>
<td>Hospitalized for 4-9 days</td>
<td>187 (50)</td>
</tr>
<tr>
<td>Stayed in the hospital ≥10 days</td>
<td>8 (0)</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>Nonoperative</td>
<td>288 (51)</td>
</tr>
<tr>
<td>Surgery</td>
<td>243 (43)</td>
</tr>
<tr>
<td>Transferred to other health facility</td>
<td>6 (1)</td>
</tr>
<tr>
<td>Died</td>
<td>31 (5)</td>
</tr>
</tbody>
</table>
A Practical Rapid Review Guide

- Guidance for conduct of rapid reviews for health policy and systems research developed in collaboration with WHO
- WHO guide recommends researchers tailor methods to needs of decision-makers
- Several ways that rapid reviews can be streamlined to accommodate decision-makers’ needs related to both scope of review and timeliness across all steps of review process
  - Link to guide: Rapid reviews to strengthen health policy and systems: a practical guide
  - Link to teaching slides: Learning Modules

Cochrane Guidance on Rapid Review Conduct

- The Cochrane Rapid Reviews Methods Group (RRMG) has developed provisional rapid review methods recommendations for Cochrane and others in the wider knowledge synthesis community to use.

  - Link to full publication: https://www.jclinepi.com/article/S0895-4356(20)31146-X/pdf
Rapid review methods more challenging during COVID-19

Key messages

- COVID-19 pandemic has created several unique challenges to conducting rapid review, including:
  - Urgency of the request (5-10 days)
  - Finding all relevant evidence
  - Interpreting results when clear and direct evidence does not exist, and
  - Sharing the results widely

Read full article: https://www.jclinepi.com/article/S0895-4356(20)30616-8/fulltext
Questions?
<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Items</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.</td>
<td><strong>Opening remarks and introductions</strong></td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>(15 minutes + 5</td>
<td>Defining rapid reviews and how they differ from other knowledge</td>
<td></td>
</tr>
<tr>
<td>minute discussion)</td>
<td>synthesis approaches</td>
<td></td>
</tr>
<tr>
<td>1:50 p.m.</td>
<td><strong>Tailoring rapid review methods according to the decision-maker needs</strong></td>
<td>Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko</td>
</tr>
<tr>
<td>(30 minutes +5</td>
<td>(30 minutes +5 minutes for Q&amp;A)</td>
<td></td>
</tr>
<tr>
<td>minutes for Q&amp;A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:25 p.m.</td>
<td><strong>Group Activity 1: Scenario</strong></td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>(30 minutes)</td>
<td>Learners (groups of 5-7) will be given a scenario of a COVID-19-related</td>
<td></td>
</tr>
<tr>
<td></td>
<td>topic from a decision maker. They will be asked to tailor the methods to</td>
<td></td>
</tr>
<tr>
<td></td>
<td>answer the research question.</td>
<td></td>
</tr>
<tr>
<td>2:55 p.m.</td>
<td><strong>Health Break</strong></td>
<td></td>
</tr>
<tr>
<td>(10 minutes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:05 p.m.</td>
<td><strong>Discerning how to assess the quality of rapid reviews</strong></td>
<td>Dr. Nancy Santesso</td>
</tr>
<tr>
<td>(15 minutes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:20 p.m.</td>
<td><strong>Effectively engaging patient and public partners in rapid reviews</strong></td>
<td>Ms. Maureen Smith Dr. François-Pierre Gauvin</td>
</tr>
<tr>
<td>(30 minutes +5</td>
<td>(30 minutes +5 minutes for Q&amp;A)</td>
<td></td>
</tr>
<tr>
<td>minutes for Q&amp;A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:55 p.m.</td>
<td><strong>Group Activity 2: Scenario</strong></td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>(30 minutes)</td>
<td>Learners (groups of 5-7) will be given a rapid review scenario for which</td>
<td></td>
</tr>
<tr>
<td></td>
<td>they will come up with a strategy on how to meaningfully involve patient</td>
<td></td>
</tr>
<tr>
<td></td>
<td>partners.</td>
<td></td>
</tr>
<tr>
<td>4:25 p.m.</td>
<td><strong>Closing Remarks</strong></td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>(5 minutes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td><strong>Adjourn</strong></td>
<td></td>
</tr>
</tbody>
</table>
Tailoring Rapid Review Methods According to the Decision-Maker Needs

Maureen Dobbins
PhD, RN
Scientific Director, National Collaborating Centre for Methods and Tools
Professor, School of Nursing, McMaster University

Sarah Neil-Sztramko
PhD, MSc
Knowledge Translation Advisor, National Collaborating Centre for Methods and Tools
Assistant Professor, Department of Health Research Methods, Evidence and Impact (HEI)
Rapid reviews in response to public health decision maker needs

Presenters: Dr. Sarah Neil-Sztramko, PhD
Dr. Maureen Dobbins, RN, PhD

June 30, 2021
NCCMT Products and Services

- Registry of Methods and Tools
- Networking and Outreach
- Online Learning Opportunities
- Video Series
- Workshops
- Public Health+
Presenters

Dr. Sarah Neil-Sztramko, PhD
National Collaborating Centre for Methods and Tools

Dr. Maureen Dobbins, RN, PhD
National Collaborating Centre for Methods and Tools
EIDM during COVID-19

NEED

CAPACITY
Rapid Evidence Service

- Urgent and ongoing need for synthesized evidence; little to no capacity among front line public health service delivery organizations

- Pivot from synthesis training and support to conducting evidence syntheses

- Response to public health decision makers’ requests for evidence on priority public health questions
Methods: Rapid Evidence Service

- NCCMT prioritizes questions from received requests
- Modified steps from the *NCCMT Rapid Review Guidebook*
- “Relay race”
- Reviews completed within 5-10+ days
RES Team

- NCCMT Scientific Director
- NCCMT Operational Lead
- RES Scientific Lead
- Rapid Review Leads (3-4)
- RES Coordinator
- Rapid Review Search Lead
- Rapid Review Search Staff (1-2)
- Rapid Review Support Staff (3-4)
Receive and prioritize questions

- Questions from federal, provincial/territorial, local organizations + international

- Weekly team meeting
  - Assess progress on current reviews
  - Assess capacity to start new reviews

- Prioritization
  - Avoid duplication
    - COVID-END
  - Urgency/relevance of question to Canadian context
  - Content expertise in house to address question
  - Availability of *useful* evidence
Formulate Question

• PICO or PS (where possible)

• Collaboration with requestor

• Used to set inclusion/exclusion criteria

Living Rapid Review Update 14: What is the specific role of daycares and schools in COVID-19 transmission?

<table>
<thead>
<tr>
<th></th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Children and adolescents aged 1–18</td>
<td>Infants</td>
</tr>
<tr>
<td>Intervention</td>
<td>Exposure to or diagnosis of COVID-19</td>
<td></td>
</tr>
<tr>
<td>Comparisons</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td>Confirmed or suspected case of COVID-19</td>
<td></td>
</tr>
<tr>
<td>Setting</td>
<td>Schools, daycares, camps</td>
<td>Extra-curricular activities such as sports teams</td>
</tr>
</tbody>
</table>
Searching

• Search strategy outlined
  • Predominantly COVID-19 databases (some exceptions)

• Search for:
  • English language
  • Peer-reviewed sources, and pre-prints

• Depending on question:
  • Grey literature
  • Jurisdictional data

• Try to prioritize syntheses before single studies
Databases searched

**COVID-19 Specific Databases**
- LitCovid: Pubmed’s curated COVID-19 literature hub
- WHO’s Global literature on coronavirus disease
- COVID-19 Evidence Alerts from McMaster PLUS™
- L·OVE: COVID-19 Living Overview of the Evidence
- Cochrane Coronavirus (COVID-19) Special Collections

**General Databases**
- Guidelines International Network (GIN)
- Trip Medical Database
- MedRxiv preprint server
- Prospero Registry of Systematic Reviews

**Relevant websites/repositories**
- NCCMT COVID-19 Rapid Evidence Reviews
- NCC websites
- Public Health Ontario
- Institute national d’excellence en santé et en services sociaux (INESSS)
- BCCDC
- Alberta Health Services
- USHER Network for COVID-19 Evidence Reviews
- Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report
- Oxford COVID-19 Evidence Service
- Public Health England
Screening

- Single reviewer title & abstract screening
  - Export to Distiller SR
    - New: Use of DAISY re-rank and AI function
  - Manual screening of some sources
    - Track in excel
- Single reviewer full text screening
  - Double checked during summary writing
Data extraction

- Data extracted by one reviewer, checked by RR lead

- Key information
  - Study design
  - Population
  - Setting
  - Summary of findings
  - Quality rating
  - Other info as needed

Table 3: Single Studies

<table>
<thead>
<tr>
<th>Reference</th>
<th>Date Released</th>
<th>Study Design</th>
<th>Population</th>
<th>Setting</th>
<th>Summary of Findings</th>
<th>Quality Rating</th>
</tr>
</thead>
</table>
| Jones, A., Watts, A. G., Khan, S. U., Forsyth, J., Brown, K., Costa, A. P., ... Stall, N. M. (2021). *Impact of a Public Policy Restricting Staff Mobility Between Nursing Homes in Ontario, Canada During the COVID-19 Pandemic*. *Journal of Post-Acute and Long-Term Care Medicine*. Epub ahead of print. | Jan 25, 2021 | Quasi-experimental | Staff in 629 LTC facilities | Ontario, Canada | Mobile device GPS location data were analyzed 7 weeks before and after an emergency order restricting staff to work in a single LTC facility in a 14-day period. After the order was implemented:  
  - Number of LTCs with ≥ 1 staff connection decreased from 42.7-12.7% (p<0.001)  
  - Mean number of connected staff per LTC decreased from 3.30 to 0.77 (p<0.001)  
  - Number of LTCs in outbreak increased from 23.9-46.9% (statistical significance not reported).  
  - LTCs with more connections:  
    - Were located in larger communities  
    - Had more beds  
    - Were part of-for-profit LTC chains  
  Data limitations prevented time trend analyses, and user consent for data sharing may underestimate staff mobility. | High |
Critical appraisal = Critically important

• By the end of April 2020, preprints accounted for approximately 40% of all English-language COVID-19 scientific work (Fraser, 2020)

• Few syntheses appraising evidence

• How to identify the most trustworthy findings?
Critical appraisal

• Completed by one reviewer, verified by a second

• Conflicts resolved through discussion, input from review lead as needed

• A variety of appraisal tools are used depending on design
  • AMSTAR 1 (Systematic Reviews)
  • AGREE II (Guidelines)
  • Joanna Briggs Institute Checklists for all other designs

• Each study rated as strong, moderate, low quality
GRADE

- Grading of Recommendations, Assessment, Development, and Evaluation

- *How likely are the findings to change with more evidence?*

- Used to assess certainty of findings based on eight domains
  - Risk of bias (quality assessment)
  - Inconsistency of effects
  - Indirectness of interventions/outcomes
  - Imprecision in effect estimate
  - Publication bias
  - Magnitude of effect
  - Dose-response relationship
  - Accounting for confounding

- Certainty of findings rated as: very low, low, moderate, strong
Final Product

• Question

• Executive Summary
  • Key findings and certainty
  • What has changed (update)
  • Overview of evidence and knowledge gaps

• Methods

• Results
  • Tables

Rapid Review: What is known about the risk of COVID-19 transmission across different indoor settings in the community such as restaurants and gyms?

Prepared by: The National Collaborating Centre for Methods and Tools
Date: November 4, 2020

Suggested Citation:
National Collaborating Centre for Methods and Tools. (2020, November 4). What is known about the risk of COVID-19 transmission across different indoor settings in the community such as restaurants and gyms. https://www.nccmt.ca/knowledge-repositories/covid-19-rapid-evidence-service

Please Note: An update of this review may be available. Access the most current version of this review by visiting the National Collaborating Centre for Methods and Tools COVID-19 Rapid Evidence Service at the above link.

© 2020, National Collaborating Centre for Methods and Tools, McMaster University. All rights reserved.
The National Collaborating Centre for Methods and Tools (NCCMT) is hosted by McMaster University and funded by the Public Health Agency of Canada. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.

This Rapid Review is for general information purposes only. The information provided in this Rapid Review is provided “as is” and McMaster University makes no warranties, promises and/or representations of any kind, expressed or implied, as to the nature, standard, accuracy, completeness, reliability or otherwise of the information provided in this Rapid Review, nor to the suitability or otherwise of the information to your particular circumstances. McMaster University does not accept any responsibility or liability for the accuracy, content, completeness, legality, reliability or use of the information contained in this Rapid Review.

The authors declare they have no conflicts of interest to report.

November 4, 2020
Executive Summary

• Background:
  • 1-2 paragraphs

• Key Points:
  • 3-5 main themes linked to certainty (GRADE)

• Overview of evidence and knowledge gaps
  • 3-5 statements on state of the evidence and major gaps (ie equity issues)

For Updates:
• 4th paragraph: RE what has changed since previous version
Summary of Findings (Quantitative)

• Per outcome:
  • Study design
  • Number of studies
  • Overall certainty

• Reasons for upgrading/downgrading provided in legend
Summary of Findings (Qualitative)

- Per outcome:
  - Key finding
  - Study design
  - Number of studies
  - Overall certainty
  - Explanation of GRADE assessment

<table>
<thead>
<tr>
<th>Key Finding (Consideration for parents)</th>
<th>Number of studies contributing to this finding</th>
<th>GRADE-CERQual assessment of confidence in the evidence</th>
<th>Explanation of GRADE-CERQual assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trust, or lack of trust, in health care providers or government</td>
<td>Syntheses 8, Single 7</td>
<td>Moderate confidence</td>
<td>Minor concerns regarding methodological limitations, relevance</td>
</tr>
<tr>
<td>Perceived safety of vaccines</td>
<td>Syntheses 6, Single 7</td>
<td>Moderate confidence</td>
<td>Minor concerns regarding methodological limitations, relevance</td>
</tr>
<tr>
<td>Satisfaction with amount and sources of information about vaccination</td>
<td>Syntheses 6, Single 8</td>
<td>Moderate confidence</td>
<td>Minor concerns regarding methodological limitations, relevance</td>
</tr>
<tr>
<td>Risk assessment of disease versus vaccination</td>
<td>Syntheses 4, Single 7</td>
<td>Moderate confidence</td>
<td>Minor concerns regarding methodological limitations, relevance</td>
</tr>
<tr>
<td>Parental choice and preference for alternative health approaches</td>
<td>Syntheses 6, Single 13</td>
<td>Moderate confidence</td>
<td>Minor concerns regarding methodological limitations, relevance</td>
</tr>
</tbody>
</table>
Dissemination: Rapid Evidence Service

- COVID-19 Rapid Evidence Service: nccmt.ca/res
- 35+ reviews & 30 updates (June 2021)
- Posted to the NCCMT’s website
- E-mail notifications – subscription and targeted
- Social media
- Monthly newsletter
- McMaster communications
Impact

- > 25 000+ page views, June 2020 – April 2021
- Priority questions from various organizations (e.g. WHO, Public Health Ontario, public health units)
- Collaborated with Public Health England on an update
- Email subscribers in nearly all provinces and territories
- Reviews indexed in various databases and updates
- Media coverage in over 30 outlets

Accessed in >69 countries
Continuous challenges

• Balancing rigour with feasibility
• Minimizing duplication
• Getting the info into the right hands at the right time for decision making
• Proactive vs. reactive

• When to consider evidence “out of date”?
• How useful is evidence from other jurisdictions to Canada?
• Signal to noise ratio, low quality evidence
Conclusion & Implications

• Implementation of a strategy that resulted in rapidly coordinated efforts on a national scale

• Reduce duplication and disseminate quality evidence into the hands of decisions makers

• Continuous evolution of methods as COVID evidence changes

• Transitioning to collaboration and supporting other organizations to conduct high quality rapid reviews
RES Team
Maureen Dobbins, RN, PhD
Sarah Neil-Sztramko, PhD
Susan Snelling, PhD
Emily Belita, RN, PhD
Emily Clark, MSc

Robyn Trainor, MSc
Leah Hagerman, MPH
Izabelle Siqueira, MPH
Taylor Colangeli
## Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Items</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 1:30 p.m. (15 minutes + 5 minute discussion) | **Opening remarks and introductions**  
Defining rapid reviews and how they differ from other knowledge synthesis approaches | Dr. Andrea Tricco                                                |
| 1:50 p.m. (30 minutes + 5 minutes for Q&A)  | **Tailoring rapid review methods according to the decision-maker needs**                           | Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko                  |
| 2:25 p.m. (30 minutes)       | **Group Activity 1: Scenario**  
Learners (groups of 5-7) will be given a scenario of a COVID-19-related topic from a decision maker. They will be asked to tailor the methods to answer the research question. | Breakout Rooms                                                  |
| 2:55 p.m. (10 minutes)       | **Health Break**                                                                                  |                                                                 |
| 3:05 p.m. (15 minutes)       | **Discerning how to assess the quality of rapid reviews**                                         | Dr. Nancy Santesso                                               |
| 3:20 p.m. (30 minutes + 5 minutes for Q&A) | **Effectively engaging patient and public partners in rapid reviews**                           | Ms. Maureen Smith  
Dr. François-Pierre Gauvin                                        |
| 3:55 p.m. (30 minutes)       | **Group Activity 2: Scenario**  
Learners (groups of 5-7) will be given a rapid review scenario for which they will come up with a strategy on how to meaningfully involve patient partners. | Breakout Rooms                                                  |
| 4:25 p.m. (5 minutes)        | **Closing Remarks**                                                                               | Dr. Andrea Tricco                                                |
| 4:30 p.m.                    | **Adjourn**                                                                                      |                                                                 |
Group Activity: Scenario 1
Tailoring the methods of a rapid review
Scenario

- You are a researcher who has received a request from the Public Health Agency of Canada (PHAC) to conduct a rapid review on the following question:
  - What is known about reasons for vaccine confidence and uptake in populations experiencing inequities?

- In answering this question, PHAC would like you to look at qualitative literature, as there is currently another research team synthesizing the quantitative literature.

In your breakout rooms, discuss how you would tailor your rapid review methodology to answer the research question. Be sure to think about:
- What vaccines you should include (as the question does not solely focus on COVID-19 vaccines)
- What types of evidence should be included
- Any special considerations for inclusion of specific types of evidence (e.g., populations experiencing inequities)
Scenario

- You are a researcher who has received a request from the Public Health Agency of Canada (PHAC) to conduct a rapid review on the following question:
  - What is known about reasons for vaccine confidence and uptake in populations experiencing inequities?

- In answering this question, PHAC would like you to look at qualitative literature, as there is currently another research team synthesizing the quantitative literature.

In your breakout rooms, discuss how you would tailor your rapid review methodology to answer the research question. Be sure to think about:
  - What vaccines you should include (as the question does not solely focus on COVID-19 vaccines)
  - What types of evidence should be included
  - Any special considerations for inclusion of specific types of evidence (e.g., populations experiencing inequities)
<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Items</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.</td>
<td><strong>Opening remarks and introductions</strong></td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>(15 minutes + 5</td>
<td>Defining rapid reviews and how they differ from other knowledge</td>
<td></td>
</tr>
<tr>
<td>minute discussion)</td>
<td>synthesis approaches</td>
<td></td>
</tr>
<tr>
<td>1:50 p.m.</td>
<td>**Tailoring rapid review methods according to the decision-maker</td>
<td>Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko</td>
</tr>
<tr>
<td>(30 minutes +5</td>
<td>needs</td>
<td></td>
</tr>
<tr>
<td>minutes for Q&amp;A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:25 p.m.</td>
<td><strong>Group Activity 1: Scenario</strong></td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>(30 minutes)</td>
<td>Learners (groups of 5-7) will be given a scenario of a COVID-19-related topic from a decision maker. They will be asked to tailor the methods to answer the research question.</td>
<td></td>
</tr>
<tr>
<td>2:55 p.m.</td>
<td><strong>Health Break</strong></td>
<td></td>
</tr>
<tr>
<td>(10 minutes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:05 p.m.</td>
<td><strong>Discerning how to assess the quality of rapid reviews</strong></td>
<td>Dr. Nancy Santesso</td>
</tr>
<tr>
<td>(15 minutes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:20 p.m.</td>
<td><strong>Effectively engaging patient and public partners in rapid reviews</strong></td>
<td>Ms. Maureen Smith Dr. François-Pierre Gauvin</td>
</tr>
<tr>
<td>(30 minutes +5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>minutes for Q&amp;A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:55 p.m.</td>
<td><strong>Group Activity 2: Scenario</strong></td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>(30 minutes)</td>
<td>Learners (groups of 5-7) will be given a rapid review scenario for which they will come up with a strategy on how to meaningfully involve patient partners.</td>
<td></td>
</tr>
<tr>
<td>4:25 p.m.</td>
<td><strong>Closing Remarks</strong></td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>(5 minutes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td><strong>Adjourn</strong></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Agenda Items</td>
<td>Presenters</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 1:30 p.m. (15 minutes + 5 minute discussion) | **Opening remarks and introductions**  
Defining rapid reviews and how they differ from other knowledge synthesis approaches | Dr. Andrea Tricco                                      |
| 1:50 p.m. (30 minutes + 5 minutes for Q&A) | **Tailoring rapid review methods according to the decision-maker needs** | Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko        |
| 2:25 p.m. (30 minutes) | **Group Activity 1: Scenario**  
Learners (groups of 5-7) will be given a scenario of a COVID-19-related topic from a decision maker. They will be asked to tailor the methods to answer the research question. | Breakout Rooms                                           |
| 2:55 p.m. (10 minutes) | Health Break                                                                 |                                                          |
| 3:05 p.m. (15 minutes) | **Discerning how to assess the quality of rapid reviews** | Dr. Nancy Santesso                                      |
| 3:20 p.m. (30 minutes + 5 minutes for Q&A) | **Effectively engaging patient and public partners in rapid reviews** | Ms. Maureen Smith and Dr. François-Pierre Gauvin       |
| 3:55 p.m. (30 minutes) | **Group Activity 2: Scenario**  
Learners (groups of 5-7) will be given a rapid review scenario for which they will come up with a strategy on how to meaningfully involve patient partners. | Breakout Rooms                                           |
| 4:25 p.m. (5 minutes) | **Closing Remarks**                                                           | Dr. Andrea Tricco                                      |
| 4:30 p.m.            | Adjourn                                                                       |                                                          |
Discerning How to Assess the Quality of Rapid Reviews

Nancy Santesso
RD, MLIS, PhD
Deputy Director, Cochrane Canada
Assistant Professor, Department of Health Research Methods, Evidence and Impact at McMaster University
How to discern the ‘quality’ of rapid reviews

Nancy Santesso, RD, PhD
Rapid reviews

• You find a rapid review

• You ask for a rapid review to be performed

• You have to do the rapid review!
Rapid Review: What is known about reasons for vaccine confidence and uptake in populations experiencing inequities?

- Across studies exploring perceptions of different vaccines, safety was a primary concern both as a motivator for seeking vaccination (i.e., to protect oneself and others from illness) and as a reason to not seek vaccination (i.e., potential side effects). The confidence in this finding is low (GRADE-CERQual) however, it is possible that this finding is a reasonable representation of the phenomenon of interest.
Rapid Review: What is known about reasons for vaccine confidence and uptake in populations experiencing inequities?

- Across studies exploring perceptions of different vaccines, safety was a primary concern both as a motivator for seeking vaccination (i.e., to protect oneself and others from illness) and as a reason to not seek vaccination (i.e., potential side effects). The confidence in this finding is low (GRADE-CERQual) however, it is possible that this finding is a reasonable representation of the phenomenon of interest.
As a decision maker, should we dedicate large amounts of resources to educate people about safety?

Are we confident that safety is a concern and a reason for uptake of vaccines?

- Across studies exploring perceptions of different vaccines, safety was a primary concern both as a motivator for seeking vaccination (i.e., to protect oneself and others from illness) and as a reason to not seek vaccination (i.e., potential side effects). The confidence in this finding is low (GRADE-CERQual) however, it is possible that this finding is a reasonable representation of the phenomenon of interest.
The authors of the review assessed the quality of the studies in the rapid review, considered the richness of the data, the coherence in the results, and other factors.

- Across studies exploring perceptions of different vaccines, safety was a primary concern both as a motivator for seeking vaccination (i.e., to protect oneself and others from illness) and as a reason to not seek vaccination (i.e., potential side effects). The confidence in this finding is low (GRADE-CERQual) however, it is possible that this finding is a reasonable representation of the phenomenon of interest.
Low confidence that safety is a concern and a reason for uptake

- Across studies exploring perceptions of different vaccines, safety was a primary concern both as a motivator for seeking vaccination (i.e., to protect oneself and others from illness) and as a reason to not seek vaccination (i.e., potential side effects). The confidence in this finding is low (GRADE-CERQual) however, it is possible that this finding is a reasonable representation of the phenomenon of interest.
Rapid Review: What is known about reasons for vaccine confidence and uptake in populations experiencing inequities?

Were ‘shortcuts’ taken? Were they appropriate?

We should probably first check if the review was well done.

Does the rapid review provide a comprehensive and accurate summary of whatever literature is out there?
AMSTAR 2

• Checklist

• Developed for systematic reviews (not specifically for rapid reviews)

• Criteria apply to rapid reviews

• I’ve included what we know from research about the impact of “shortcuts” on the summary from a review

• SYSTEMATIC
1. **Structured question and appropriate inclusion criteria**
   - If they excluded children to make it more rapid but you need information about children – then findings not accurate or comprehensive

2. **Protocol without deviations or deviations justified**
   - Rapid review indicates that they did have a protocol (although it may not be published or registered)
   - check the [https://www.nccmt.ca/covid-19/covid-19-evidence-reviews](https://www.nccmt.ca/covid-19/covid-19-evidence-reviews)
   - Check PROSPERO [https://www.crd.york.ac.uk/prospero/](https://www.crd.york.ac.uk/prospero/)
   - Check protocols Cochrane Library [https://www.cochranelibrary.com/](https://www.cochranelibrary.com/)
3. **Limitations to the search not likely to miss studies**
   - At a minimum for health interventions: Medline, Embase, Central
   - Search literature appropriate to question
   - Limiting to last X months may be justified
   - Limiting to English may not be appropriate for current COVID studies

4. **Rigorous method to select and exclude studies, and extract data**
   - While 2 people is best, 1 and another verifying data or the excluded studies may not bias the results from the review
Criteria

5. Included studies are described (and sources of funding) and the risk of bias assessed
   • at least 1 person assessing and another verifying

6. Synthesis of studies rigorously performed (meta-analysis or not)
   • Watch out for vote counting studies that were ‘statistically significant’ or not
7. Risk of bias, publication bias, heterogeneity and other factors were considered when making conclusions
   • e.g., using GRADE (or a systematic approach) to assess certainty of evidence

8. Conflict of interest of review authors reported
Key points

• A review, whether rapid or not, is a review of the literature available

• A review, if well done, should provide an accurate summary of the literature (assess whether it does using the criteria)

• A well done review, whether rapid review or not, may find a lot or little literature - we still need to know how certain we are in the effects of a treatment or reasons for vaccine uptake to make decisions
<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Items</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.</td>
<td><strong>Opening remarks and introductions</strong>&lt;br&gt;Defining rapid reviews and how they differ from other knowledge synthesis approaches</td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td>1:50 p.m.</td>
<td><strong>Tailoring rapid review methods according to the decision-maker needs</strong></td>
<td>Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko</td>
</tr>
<tr>
<td>2:25 p.m.</td>
<td><strong>Group Activity 1: Scenario</strong>&lt;br&gt;Learners (groups of 5-7) will be given a scenario of a COVID-19-related topic from a decision maker. They will be asked to tailor the methods to answer the research question.</td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>2:55 p.m.</td>
<td>Health Break</td>
<td></td>
</tr>
<tr>
<td>3:05 p.m.</td>
<td><strong>Discerning how to assess the quality of rapid reviews</strong></td>
<td>Dr. Nancy Santesso</td>
</tr>
<tr>
<td>3:20 p.m.</td>
<td><strong>Effectively engaging patient and public partners in rapid reviews</strong></td>
<td>Ms. Maureen Smith and Dr. François-Pierre Gauvin</td>
</tr>
<tr>
<td>3:55 p.m.</td>
<td><strong>Group Activity 2: Scenario</strong>&lt;br&gt;Learners (groups of 5-7) will be given a rapid review scenario for which they will come up with a strategy on how to meaningfully involve patient partners.</td>
<td>Breakout Rooms</td>
</tr>
<tr>
<td>4:25 p.m.</td>
<td><strong>Closing Remarks</strong></td>
<td>Dr. Andrea Tricco</td>
</tr>
<tr>
<td></td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Effectively Engaging Patient and Public Partners in Rapid Reviews

Maureen Smith
MEd
Chair, Cochrane Consumer Network Executive

François-Pierre Gauvin
PhD
Senior Scientific Lead, Citizen Engagement and Evidence Curation, McMaster Health Forum, McMaster University
Effectively engaging patient and public partners in rapid reviews

François-Pierre Gauvin
Co-lead, COVID-END Citizen Partnership Strategy
McMaster Health Forum
Senior Scientific Lead, Evidence Curation

Maureen Smith
Co-lead, COVID-END Citizen Partnership Strategy
Chair Cochrane Consumer Network Executive

30 June 2021
Objectives

- Patient & citizen engagement in research
- Patient & citizen engagement in COVID-19 evidence synthesis context
- Where in the process and how to engage
- Challenges & solutions
- Planning your engagement
- COVID-END in Canada’s citizen engagement
- Training & resources
Patient and Citizen Engagement in Research

- **Who is a patient?**¹
  The Canadian Institutes of Health Research uses patient to be inclusive of individuals with personal experience of a health issue and informal caregivers, including family and friends.

- **Who is a citizen?**²
  The Canadian Institutes of Health Research defines citizen as any interested representatives of the general public, consumers of health services, patients, caregivers, advocates and representatives from affected community and voluntary health organizations.

- **What is patient and citizen engagement in health research?**
  Meaningful (*not tokenistic*) and active collaboration in governance, priority setting, conducting research, and knowledge translation to ensure patients voice and priorities play a role in shaping the evidence and care they receive.

2. CIHR Jargon Buster. Available from [https://cihr-irsc.gc.ca/e/48952.html](https://cihr-irsc.gc.ca/e/48952.html)
What Does Patient and Citizen Partnership Look Like?

**What it is?**

- Working with patients and citizen to set the research agenda
- Working with patients and citizens to conceptualize the research question and design
- Working with patients citizens to develop key messages based on the findings

**What it is not?**

- Enrolling patients and citizens as a study participant to test an intervention
- Interviewing patients and citizens in a focus group or other qualitative study designs
- Observing a population to collect information on health-related outcomes
Why engage patients and the public in COVID-19 research?

- Many COVID-19 research topics are relevant to patients and citizens (e.g. public health measures, vaccines, societal/economic impacts, etc.) thus engaging them is essential.

- Patients and citizens are decision makers! They are making personal decisions that have tremendous societal impacts.

- Patient and citizen engagement in health research will help shape research and health system to be more responsive to their needs.

- Focuses on patient and citizen priorities and improves health outcomes individually and in communities.
COVID-19 - Decision-makers must make various types of decisions

- What is known about...
  - **Public-health measures** (e.g., masks and tests, curfews, quarantine)
  - **Clinical management** of COVID-19 (e.g., prescription drugs) and pandemic-related conditions (e.g., mental health and addictions issues)
  - **Health-system arrangements** (e.g., scaling hospital capacity up or down and virtual-care alternatives to in-person care)
  - **Economic and social responses** (e.g., school and public-transit changes)
Why engage patients & citizens in COVID-19 evidence synthesis?

And especially rapid evidence synthesis!

- Evidence synthesis is the backbone of policy decisions, clinical guidelines, good practices, etc. We are the end-users!
- Patients and citizens should be engaged in:
  - Prioritizing rapid review topics
  - Framing the questions and have input on outcomes
  - Interpreting the findings to make them relevant
  - Accessing the results in plain language
Engagement Spectrum

<table>
<thead>
<tr>
<th>Engagement Level</th>
<th>What</th>
<th>How</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inform</td>
<td>To provide easy to understand, objective, and balanced information to help them participate in the discussions.</td>
<td>• Plain language summary • Infographic</td>
</tr>
<tr>
<td>Consult</td>
<td>To obtain feedback on research direction, progress, outcomes, analysis and interpretation.</td>
<td>• 1-on-1 interviews • Surveys • Focus groups • Workshop</td>
</tr>
<tr>
<td>Involve</td>
<td>To work closely throughout the research process to ensure patient perspectives are consistently understood and considered</td>
<td>• Working group • Regular meetings</td>
</tr>
<tr>
<td>Collaborative</td>
<td>Engage in each aspect of the decision in research and research-related activities</td>
<td>• Advisory committee • Consensus-building • Participatory decision-making</td>
</tr>
<tr>
<td>Empower</td>
<td>To place final decision-making responsibilities</td>
<td>• Delegated decision</td>
</tr>
</tbody>
</table>
At what stages knowledge synthesis can you engage patient and citizen partners?

**Pre-conception**
- Identify research gaps and prioritize the health issues

**Conception**
- Identify patient relevant outcomes

**Conduct**
- Provide feedback along the way as needed

**Analysis**
- Contextualize data analysis

**Dissemination**
- Co-produce plain language summaries and
Engagement Opportunity – Planning Stage

During the project planning stage (the work plan or protocol)

- Help develop the research question the project will address.
- Help define the outcomes that the research should explore.
  - This might include suggesting additional outcomes that would be of interest to patients and citizens, or selecting outcomes of greatest importance to patients and citizens.
- Provide input on how information is collected and synthesized.
  - This might include providing feedback on whether it is appropriate to group particular symptoms, treatments or health conditions together in the synthesis.
During the report writing stage

- Provide feedback on a draft of the review results
  - Patients/citizen partners might be asked for specific feedback about whether they agree with how the results have been interpreted, or asked to give suggestions for what the key messages should be.

- Help develop the plain language summary of the research findings
  - This might include patient/citizen leading the writing with support from the research team or vice versa.

- Comment on the plans for sharing (disseminating) the research findings
  - They might make suggestions to help reach the general public or particular population groups.
Acknowledging patient/citizen partner contributions

- Patient/citizen partners should be acknowledged in your research report
- Depending on your format, can be listed as Project Contributors or in the Acknowledgement section
- Identify that they are patient or citizen/public partners
- Include affiliation (such as community organization, patient group, etc.) if appropriate and desirable
Engagement Opportunity – Co-authorship

Patient and citizen partner co-authors

- In some instances, patient/citizen partners can become core members of the research project team

- This would mean they provide input throughout the conduct of the research project

- Co-authorship will be offered as per the recommendations of the International Committee of Medical Journal Editors
## Challenges & Solutions

<table>
<thead>
<tr>
<th>Challenges</th>
<th>Solutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quick turnaround and tight timelines. Some projects are completed within 5-10 business days</td>
<td>Be clear about the timelines so that patient/public partners can decide if they can commit to this schedule</td>
</tr>
<tr>
<td>Not enough time to train researchers and patient/citizen partners on how to meaningfully collaborate</td>
<td>We’re offering training and resources for researchers and patient/citizen partners.</td>
</tr>
<tr>
<td>Difficult to build relationship with rapid projects</td>
<td>Patient/citizen partners understand the COVID reality and the impact this has on engagement. Agree on roles and responsibilities from the onset of your collaboration.</td>
</tr>
</tbody>
</table>
How do I get started?
Use our planning tool

Citizen Engagement Template for Researchers

<table>
<thead>
<tr>
<th>Principal researcher and institution</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Email:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contact person for citizen engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Email:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of evidence synthesis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Is it a living evidence synthesis? If so, how often is it updated?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>
What is the topic?

What is the timeline? (Start date, end date)

At what step(s) to you foresee engaging with citizens?

- At the start – to review question, approach, outcomes
- At the analysis stage – to contribute to interpretation
- Towards the end – to review key messages
- At the plain language summary stage
What is the anticipated time commitment?

Please be as specific as possible, especially for living evidence synthesis. Is it weekly? bi-weekly? monthly?

How will you communicate with citizens?

- Virtual meetings (Zoom, Microsoft Teams, etc.)
- What’s App
- Email
- Telephone
Why use the template?

- Planning for your research team
  - Assign one contact person to liaise with your patient/citizen partners
  - Quite common to allow for 5-7 hours of patient/public engagement but will vary depending on your project and the degree of involvement
  - What is feasible for you? At what steps would you like to engage?

- Information for potential patient/public partners
  - Can they commit to the timeline?
  - Is it a topic of interest?
COVID-END commitment to citizen partnerships

We use the word ‘citizen’ here to mean:

- citizens – whether as taxpayers or voters or in other roles, and regardless of their formal citizenship status and whether they may also currently be considered a patient – who may be affected by the economic and social responses to the pandemic;
- communities, by which we mean groups of citizens – whether defined by geography, lived experience with particular conditions or treatments (or health determinants), ethnocultural group or other factors – who may be affected by the economic and social responses to the pandemic;
- patients in the usual sense of those receiving care in the health system;
- potential patients who need care, whether or not they are receiving it now; and
- families of and caregivers to these patients or potential patients.

The term engagement captures a range of efforts to involve citizens in the work of COVID-END, ranging from: communication, consultation, partnership and shared leadership.
It started globally: COVID-END Global
COVID-END in Canada

- COVID-END is a time-limited network that brings together more than 50 of the world’s leading evidence-synthesis, technology-assessment and guideline-development groups around the world
- Commitment to citizen partnership since August 2020
  - Citizen-partnership strategy
  - Citizens being members of the partners’ meetings, horizon-scanning panel, and working groups
- In January 2021, the Government of Canada, through the Canadian Institutes of Health Research, invested 1M$ in COVID-END to support Canadian needs
  - More than 40 evidence-synthesis teams from across the country
Why a pool of citizens?

- A “pool” of Canadian citizens who will be called upon to provide their perspectives on a number of our evidence synthesis products
  - provide your perspective to frame questions
  - identify outcomes that are important to citizens
  - providing feedback on the synthesis (sometimes referred to as peer review)
  - contributing plain language summaries and infographics based on the findings
COVID-END in Canada citizen pool

- 20 citizens recruited from 80 applicants, aiming for diversity:
  - age
  - gender
  - socio-economic status
  - ethnocultural
  - geographical (e.g., across Canada, rural/urban/remote areas)
  - lived experiences (e.g., had COVID, immunocompromised, living with other health conditions, economic, school age children, work with refugees, etc.)
- More targeted recruitment to occur to bring additional diversity
Patient Partner Engagement on Rapid Reviews

- To improve patient partner engagement on research projects, namely rapid reviews, the SPOR Evidence Alliance has partnered with patient partners Maureen Smith and Janet Gunderson to co-develop the Patient Partner Panel for Rapid Reviews training program.

- **Vision:** To facilitate meaningful and valuable patient-researcher collaboration in rapid review projects.

- **Purpose**
  - Present a basic understanding of knowledge synthesis and rapid reviews to ensure that public/patient partners can provide feedback and collaborate meaningfully in rapid review projects.
  - To efficiently on-board patient partners to various rapid review projects conducted or administered through the SPOR Evidence Alliance and our collaborators.
  - To improve the overall collaborative experiences for both patient partners and researchers working together on rapid review projects.
  - To minimize barriers to successful collaboration associated with the rapid nature of these research projects.

24 patient partners completed the training program in May 2021.
COVID-END & SPOR Evidence Alliance Evidence Synthesis Products

- Rapid evidence profiles
- Living evidence profile or synthesis
- Evidence summaries
- Scoping reviews
- Rapid reviews
- Living guidelines

COVID-END inventory:
https://www.mcmasterforum.org/networks/covid-end/resources-specific-to-canada/for-decision-makers/scan-evidence-products

SPOR Evidence Alliance inventory:
https://sporevidencealliance.ca/key-activities/covid-19-evidence-synthesis/
Public Engagement in Action

- What is known about anticipated COVID-19 vaccine roll-out elements?
  - Securing and distributing a reliable supply of vaccines and supplies
  - Allocating vaccines and supplies equitably
  - Communicating vaccine-allocation plans and the safety and effectiveness of vaccines
- Updated each month

What is known about anticipated COVID-19 vaccine roll-out elements?

- Securing and distributing a reliable supply of vaccines and supplies
- Allocating vaccines and supplies equitably
- Communicating vaccine-allocation plans and the safety and effectiveness of vaccines

Updated each month

Box 1: Our approach
We identified new research evidence addressing the question by searching the COVID-END Immune of best evidence evidence and the COVID-END guide to key COVID-19 evidence sources. We updated the evidence summary by searching jurisdiction-specific sources of evidence listed in the key COVID-19 evidence sources, and by hand searching government and reliable websites. We selected eight countries (Australia, China, France, Germany, Israel, New Zealand, the U.K., and the U.S.) that are advanced in their thinking and/or experience with the roll-out of the COVID-19 vaccine.

We searched for guidelines that were developed using a robust process (e.g., GRADE), full systematic reviews (or review-detailed products such as overviews of systematic reviews), rapid reviews, protocols for systematic reviews, and titles/abstracts for systematic reviews or rapid reviews that have been identified as either being conducted or prioritized to be conducted. Single studies were only included if no relevant systematic reviews were identified.

We appraised the methodological quality of full systematic reviews and rapid reviews using AMSTAR. Note that quality appraisal scores for rapid reviews are often lower because of the methodological shortcuts that need to be taken to accommodate preplanned timelines. AMSTAR uses overall quality on a scale of 0 to 11, where 11/11 represents a review of the highest quality. It is important to note that the AMSTAR tool was developed to assess reviews focused on clinical interventions, so not all criteria apply to systematic reviews pertaining to delivery, financial or governance arrangements within health systems or to broader social systems.

This update of the living evidence profile was prepared in the equivalent of two days of a “full-court press” by all involved staff, and will continue to be updated twice a month to provide evidence updates that can support COVID-19 vaccine roll-out.
**Training**

**Patient/Public Partners**
- COVID-END Onboarding session – April 2021
- SPOR Evidence Alliance inaugural mini-course (approx. 10 hours) co-designed with two patient partners – May 2021
  - Patient/Public Engagement in Rapid Reviews
  - 24 attendees, including 10 from the COVID-END pool

**Researchers**
- COVID-END and SPOR Evidence Alliance webinars include patient/public engagement
- More to come !!!!
COVID-END – Resources specific to Canada

- Annotated resource list
- Citizen Engagement template for researchers
- Plain language template

https://www.mcmasterforum.org/networks/covid-end/resources-specific-to-canada/for-researchers
SPOR Evidence Alliance Resources

Patient and Citizen Engagement in Research – Complete Tip Sheet

Patient and Public Partner Engagement in Research – Tip Sheet
We can help!

- If you would like to make use of our pool, we’re happy to connect you with patient/citizen partners.
- Complete the citizen engagement template for researchers and send us an email!
- We’ll send an invitation to members of our pool who would be good candidates for your review and connect you!
Compensation

- Work out a policy that works for you!
- COVID-END uses the SPOR Evidence Alliance Appreciation Policy for its citizen contributors
Appreciation policy

- Based on SPOR Evidence Alliance co-produced guidelines
  - A form is provided to keep track of hours (preparation time and meeting time)

## Citizen partner activity log

<table>
<thead>
<tr>
<th>First and Last Name</th>
<th>Period of engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Activity name | Description (optional) | Date of activity | Number of hours
--- | --- | --- | ---
**Examples:**
- Participation in onboarding webinar
- Participation in citizen engagement training
- Preparation for, and participation in meeting of the Citizen Partners Task Group
- Contribution to preparation of rapid review or other evidence-synthesis product
- Review plain language summary of evidence synthesis product
- Preparation for, and participation in meeting of horizon scanning panel
- Preparation for, and participation in meeting of co-investigators

**Occasionally:**
- Prepare/ deliver presentation
- Contribute to event utilization

### Total hours contributed

**By signing below, you are acknowledging that you completed the activities above as part of the citizen partnership engagement initiative of COVID-END and that you will be compensated in cash via cheque.**

If however you do not wish to be compensated, please check the box below:

- [ ] I do not wish to receive any form of payment

**Citizen partners residing in Canada and USA**

<table>
<thead>
<tr>
<th>First and Last Name:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mailing Address:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Social Insurance Number: Canadian residents ONLY**

In order to keep this information private please call or text Julie Baird, Lead of Operations, at 289-237-0368 to provide it in confidence.

<table>
<thead>
<tr>
<th>Phone:</th>
<th>Email:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signature:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Thank You - Merci

Don’t hesitate to contact us!

François-Pierre Gauvin

gauvinf@mcmaster.ca

Maureen Smith

maureen_smith@rogers.com
QUESTIONS?
## Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Items</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 1:30 p.m.             | **Opening remarks and introductions**  
Defining rapid reviews and how they differ from other knowledge synthesis approaches | Dr. Andrea Tricco                                                        |
| 1:50 p.m.             | **Tailoring rapid review methods according to the decision-maker needs**     | Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko                           |
| 2:25 p.m.             | **Group Activity 1: Scenario**  
Learners (groups of 5-7) will be given a scenario of a COVID-19-related topic from a decision maker. They will be asked to tailor the methods to answer the research question. | Breakout Rooms                                                            |
| 2:55 p.m.             | Health Break                                                                 |                                                                           |
| 3:05 p.m.             | **Discerning how to assess the quality of rapid reviews**                    | Dr. Nancy Santesso                                                       |
| 3:20 p.m.             | **Effectively engaging patient and public partners in rapid reviews**        | Ms. Maureen Smith, Dr. François-Pierre Gauvin                             |
| 3:55 p.m.             | **Group Activity 2: Scenario**  
Learners (groups of 5-7) will be given a rapid review scenario for which they will come up with a strategy on how to meaningfully involve patient partners. | Breakout Rooms                                                            |
| 4:25 p.m.             | **Closing Remarks**                                                          | Dr. Andrea Tricco                                                        |
| 4:30 p.m.             | Adjourn                                                                      |                                                                           |
Group Activity: Scenario 2

Meaningfully engaging patient partners in rapid reviews
Scenario

- The following rapid review was completed with a short turn-around time
- **Organization that requested the review:** The Canadian Frailty Network
- **Research question:** How to mitigate the impact of COVID-19 on the elderly, by preventing transmission among older adults (60 years and above) living in long-term care?
- **Lead Investigator:** Dr. Andrea Tricco
- **Time to complete review:** 24 Days

Although patient partners weren’t engaged in this review, in your breakout rooms, explore some opportunities where patients could have been engaged.

Group Activity

- 20 minutes to discuss in small groups
- 10 minutes for rapporteurs to report back to larger groups and discuss

YOUR TASK

- How would you plan and carry out patient/public engagement for this review?
  - What are the opportunities and facilitators?
  - What are the barriers?
Consider opportunities for patient partner engagement during the rapid review process

During the project planning stage (the work plan or protocol)

During the report writing stage

Be a patient and public partner co-author
Breakout Rooms
Preventing the Transmission of Coronavirus (COVID-19) in Older Adults Aged 60 Years and Above Living in Long-Term Care: A Rapid Review

Dr. Andrea C Tricco
Nominated Principal Investigator
SPOR Evidence Alliance
Rapid Review

- **Organization that requested the review:** The Canadian Frailty Network
- **Research question:** How to mitigate the impact of COVID-19 on the elderly, by preventing transmission among older adults (60 years and above) living in long-term care?
- **Lead Investigator:** Dr. Andrea Tricco
- **Time to complete review:** 24 Days

Although patient partners weren’t engaged in this review, let’s explore some opportunities where patients could have been engaged.

Opportunities for patient partner engagement during the rapid review process

<table>
<thead>
<tr>
<th>During the project planning stage (the work plan or protocol)</th>
<th>During the report writing stage</th>
<th>Be a patient and public partner co-author</th>
</tr>
</thead>
</table>

---

National Collaborating Centre for Methods and Tools
Centre de collaboration nationale des méthodes et outils
Cochrane Canada
COVID-END COVID-19 Evidence Network to support Decision-making ... in Canada
SPOR Evidence Alliance
Alliance pour des données probantes de la SRAP
Strategy for Patient-Oriented Research
Putting Patients First
## During the project planning stage (the work plan or protocol)

<table>
<thead>
<tr>
<th>Steps Followed</th>
<th>Opportunities for Engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worked with decision-makers at the Canadian Frailty Network to develop the research question and outcomes of interest.</td>
<td></td>
</tr>
<tr>
<td>Used the following tool to determine the appropriate study design.</td>
<td></td>
</tr>
<tr>
<td>- What Review Is Right For You?</td>
<td></td>
</tr>
<tr>
<td><a href="https://whatreviewisrightforyou.knowledgetranslation.net/">Link</a></td>
<td></td>
</tr>
<tr>
<td>Registered our research question to avoid duplication.</td>
<td></td>
</tr>
<tr>
<td>- National Collaborating Centre for Methods and Tools</td>
<td></td>
</tr>
<tr>
<td><a href="https://www.nccmt.ca/covid-19/covid-19-evidence-reviews">Link</a></td>
<td></td>
</tr>
<tr>
<td>Registered our protocol.</td>
<td></td>
</tr>
<tr>
<td>- PROSPERO</td>
<td></td>
</tr>
<tr>
<td><a href="https://www.crd.york.ac.uk/prospero">Link</a></td>
<td></td>
</tr>
</tbody>
</table>

### Barriers to Engagement
During the project planning stage (the work plan or protocol)

<table>
<thead>
<tr>
<th>Steps Followed</th>
<th>Opportunities for Engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Worked with decision-makers at the Canadian Frailty Network to develop the research question and outcomes of interest.</td>
<td>▪ Canadian Frailty Network regularly engages citizen partners in the work they do.</td>
</tr>
<tr>
<td>▪ Used the following tool to determine the appropriate study design.</td>
<td>▪ We could have leveraged this partnership and consulted their citizen partner to develop research question and prioritize outcomes that are important to them.</td>
</tr>
<tr>
<td></td>
<td>▪ Opportunity to engage citizen partners to understand the context of the research question.</td>
</tr>
<tr>
<td></td>
<td>▪ National Collaborating Centre for Methods and Tools <a href="https://www.nccmt.ca/covid-19/covid-19-evidence-reviews">Link</a></td>
</tr>
<tr>
<td>▪ Registered our research question to avoid duplication.</td>
<td>▪ Only 24 days to complete the review</td>
</tr>
<tr>
<td></td>
<td>▪ Not enough time to train research team members and patient partners on how to meaningfully collaborate</td>
</tr>
<tr>
<td>▪ Registered our protocol.</td>
<td>▪ During this time, we were in the first wave of the pandemic and the research team was adjusting to changes in their new remote work settings</td>
</tr>
<tr>
<td></td>
<td>▪ <a href="https://www.crd.york.ac.uk/prospero">PROSPERO</a></td>
</tr>
</tbody>
</table>
During the report writing stage

<table>
<thead>
<tr>
<th>Steps Followed</th>
<th>Opportunities for Engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td> Sent preliminary results and ask for a deep-dive on key issues from the</td>
<td></td>
</tr>
<tr>
<td>decision-makers at the Canadian Frailty Network.</td>
<td></td>
</tr>
<tr>
<td> Used summary of findings tables</td>
<td></td>
</tr>
<tr>
<td> Discussed implications of results with caution.</td>
<td></td>
</tr>
<tr>
<td> We were specific and transparent about study limitations and what needs</td>
<td></td>
</tr>
<tr>
<td>to be addressed in the future.</td>
<td></td>
</tr>
<tr>
<td> We worked closely with the decision-maker to interpret results to ensure</td>
<td></td>
</tr>
<tr>
<td>that the end-product was relevant and fit-for-purpose.</td>
<td></td>
</tr>
</tbody>
</table>

Barriers to Engagement
## During the report writing stage

<table>
<thead>
<tr>
<th>Steps Followed</th>
<th>Opportunities for Engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td> Sent preliminary results and ask for a deep-dive on key issues from the decision-makers at the Canadian Frailty Network.</td>
<td> Citizen partners could co-authors the report if engaged through the review process.</td>
</tr>
<tr>
<td> Used summary of findings tables</td>
<td> Hold a roundtable discussion and present key findings to the citizen partners of the Canadian Frailty Network and consult them on contextualization and interpretation of the findings.</td>
</tr>
<tr>
<td> Discussed implications of results with caution.</td>
<td> Work with citizen partners to develop a plain language summary of the findings.</td>
</tr>
<tr>
<td> We were specific and transparent about study limitations and what needs to be addressed in the future.</td>
<td></td>
</tr>
<tr>
<td> We worked closely with the decision-maker to interpret results to ensure that the end-product was relevant and fit-for-purpose.</td>
<td></td>
</tr>
</tbody>
</table>

### Barriers to Engagement

- There was an increasing demand for pandemic related rapid reviews during this time, so further discussion on the report and engagement with citizen partners was handed off to the Canadian Frailty Network decision-makers and their discretion.
## Spreading the Research Findings

<table>
<thead>
<tr>
<th>Steps Followed</th>
<th>Opportunities for Engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td>We provided results in a format relevant to the review requester.</td>
<td></td>
</tr>
<tr>
<td>We provided a 1-page summary of our findings for the decision-makers.</td>
<td></td>
</tr>
<tr>
<td>We also published our findings in a peer-reviewed journal at a later date.</td>
<td></td>
</tr>
<tr>
<td>We featured our publication and findings on our twitter profiles and websites.</td>
<td></td>
</tr>
</tbody>
</table>

### Barriers to Engagement
## Spreading the Research Findings

### Steps Followed

- We provided results in a format relevant to the review requester.
- We provided a 1-page summary of our findings for the decision-makers.
- We also published our findings in a peer-reviewed journal at a later date.
- We featured our publication and findings on our twitter profiles and websites.

### Opportunities for Engagement

- Consult citizen partners to determine if the review findings are relevant and important to patients and members of the public.
- Work together to develop the key messages.
- Work together to determine the best format and communication channels to reach patients and members of the public.

### Barriers to Engagement

- The team did not have capacity at the time to facilitate this process.
<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Items</th>
<th>Presenters</th>
</tr>
</thead>
</table>
| 1:30 p.m. (15 minutes + 5 minute discussion) | **Opening remarks and introductions**  
Defining rapid reviews and how they differ from other knowledge synthesis approaches                                      | Dr. Andrea Tricco                                |
| 1:50 p.m. (30 minutes +5 minutes for Q&A)   | **Tailoring rapid review methods according to the decision-maker needs**                                                                 | Dr. Maureen Dobbins and Dr. Sarah Neil-Sztramko |
| 2:25 p.m. (30 minutes) | **Group Activity 1: Scenario**  
Learners (groups of 5-7) will be given a scenario of a COVID-19-related topic from a decision maker. They will be asked to tailor the methods to answer the research question. | Breakout Rooms                                   |
| 2:55 p.m. (10 minutes) | **Health Break**                                                                                                                             |                                                 |
| 3:05 p.m. (15 minutes) | **Discerning how to assess the quality of rapid reviews**                                                                                   | Dr. Nancy Santesso                               |
| 3:20 p.m. (30 minutes +5 minutes for Q&A)   | **Effectively engaging patient and public partners in rapid reviews**                                                                         | Ms. Maureen Smith  
Dr. François-Pierre Gauvin                       |
| 3:55 p.m. (30 minutes) | **Group Activity 2: Scenario**  
Learners (groups of 5-7) will be given a rapid review scenario for which they will come up with a strategy on how to meaningfully involve patient partners. | Breakout Rooms                                   |
| 4:25 p.m. (5 minutes)  | **Closing Remarks**                                                                                                                         | Dr. Andrea Tricco                                |
| 4:30 p.m.             | Adjourn                                                                                                                                     |                                                 |
Closing Remarks

Thank you for attending today’s workshop!

We hope you have gained a better understanding of

1. What a rapid review is and how it differs from other knowledge synthesis approaches
2. How to tailor the methods for rapid reviews according to the decision-maker needs
3. How to assess the quality of a rapid review
4. How to effectively engage patient and public partners in rapid reviews
Andrea C. Tricco MSc, PhD
Scientist, St. Michael’s Hospital, Unity Health Toronto
Canada Research Chair Tier 2 in Knowledge Synthesis
E-mail: Andrea.Tricco@unityhealth.to
Twitter: @ATricco  

Maureen Smith MEd, Patient Partner
Chair, Cochrane Consumer Network Executive
E-mail: maureen_smith@rogers.com
Twitter: @COVID_E_N_D  

François-Pierre Gauvin PhD
Senior Scientific Lead, Citizen Engagement and Evidence Curation, McMaster Health Forum, McMaster University
Email: gauvinf@mcmaster.ca
Twitter: @COVID_E_N_D  

THANK YOU
Maureen Dobbins PhD, RN
Scientific Director, National Collaborating Centre for Methods and Tools
E-mail: dobbinsm@mcmaster.ca
Twitter: @nccmt

Sarah Neil-Sztramko MSc, PhD
Knowledge Translation Advisor, National Collaborating Centre for Methods and Tools
E-mail: neilszts@mcmaster.ca
Twitter: @sarah_ns_phd

Nancy Santesso RD, MLIS, PhD
Deputy Director, Cochrane Canada
Email: santesna@mcmaster.ca

THANK YOU
Funding Acknowledgement

- The Strategy for Patient-Oriented Research Evidence Alliance is supported by the Canadian Institutes of Health Research (CIHR) under Canada’s SPOR initiative.

- COVID-19 Evidence Network to support Decision-making (COVID-END) is funded by the Canadian Institutes of Health Research (CIHR) through a one-year operating grant.
Acknowledgements

- Sabrina Chaudhry
- Wasifa Zarin
- Sonia Thomas
- Nazia Darvesh
- Fariha Mosaddeque
- Amanda Parker
- Areej Hezam
- Faryal Khan
- Shazia Siddiqui
- Sinit Michael
- Katrina Chiu
- Navjot Mann
- Dr. Sharon Straus